HOUSTON, Texas -- A major Houston university has taken a big leap in the race to battle debilitating diseases such as COVID-19. The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston-based biotech company developing novel vaccines against aggressive respiratory diseases such as coronavirus, according to a press release.
This means AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering. Varadarajan is a co-founder of AuraVax.
The vaccine is a nasal inhalant, much like FluMist. Based on pre-clinical experimentation, Varadarajan reports his technology not only elicits a mucosal immune response, but also systemic immunity, according to UH.
For more on this story, visit our partners at Houston CultureMap.
SEE ALSO: Most people try to avoid COVID-19. But thousands are signing up to be deliberately exposed
RELATED: White House rejects updated FDA guidelines on coronavirus vaccine approval
UH vaccine development could make you immune to COVID-19, experiments show
More TOP STORIES News